A5072690937- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- COVID-19 and Mental Health
Molnupiravir, EIDD-2801/MK-4482, the prodrug of active antiviral ribonucleoside analog ß-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a number RNA viruses including severe acute respiratory syndrome coronavirus 2, coronavirus, Middle East and seasonal pandemic influenza viruses.Single multiple doses molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study healthy volunteers, which included evaluation effect food on...
There is an urgent need for effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression disease 2019 (COVID-19). In a phase 2a double-blind, placebo-controlled, randomized, multicenter clinical trial, we evaluated the safety, tolerability, antiviral efficacy nucleoside analog molnupiravir in 202 unvaccinated participants with confirmed SARS-CoV-2 infection symptom duration <7 days. Participants...
Abstract Background Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression severe illness, and block transmission of acute respiratory syndrome 2 (SARS-CoV-2). We report the results a Phase 2a trial evaluating safety, tolerability, antiviral efficacy molnupiravir in treatment COVID-19 ( ClinicalTrials.gov NCT04405570 ). Methods Eligible participants included outpatients with confirmed SARS-CoV-2 infection symptom onset within...
Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of ribonucleoside analog ß-d-N4-hydroxycytidine (NHC), has activity against a number RNA viruses including severe acute respiratory syndrome coronavirus 2, coronavirus, Middle East seasonal and pandemic influenza viruses, syncytial virus. Single multiple doses molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study healthy volunteers, which included evaluation effect food on...
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious virus isolation in outpatients with disease 2019 (COVID-19) has been associated viral RNA levels and symptom duration, little is known about the host, disease, determinants of detection.
Abstract Meaningful metrics of antiviral activity are essential for determining the efficacy therapeutics in human clinical trials. Molnupiravir (MOV) is a broadly acting nucleoside analog prodrug that acts as competitive alternative substrate SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). We developed an assay, Culture-PCR, to better understand impact MOV therapy on infectious SARS-CoV-2. Culture-PCR revealed eliminated virus within 48 hours nasopharyngeal compartment, upper airway...
Abstract Background While SARS-CoV-2 infectious virus isolation in outpatients with COVID-19 has been associated viral RNA levels and symptom duration, little is known about the host, disease determinants of detection. Methods adult were enrolled within 7 days onset. Clinical symptoms recorded via patient diary. Nasopharyngeal swabs collected to quantitate by reverse transcriptase polymerase chain reaction for Vero E6-cells. antibodies measured serum using a validated ELISA assay. Results...